Comparative Pharmacology
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus NEURAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus NEURAMATE.
DIPHENYLAN SODIUM vs NEURAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
100 mg orally every 8 hours
250 mg orally three times daily; maximum 1000 mg/day.
None Documented
None Documented
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Primarily renal (90% unchanged) with 10% biliary/fecal.
Category C
Category C
Antiepileptic
Antiepileptic